MAM
IKT icon

Mystic Asset Management’s Inhibikase Therapeutics IKT Stock Holding History

Mystic Asset Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-379
Closed -$3K – 270
2021
Q4 		$3K Buy
+379
New +$4.18K ﹤0.01% 400

Other funds holding IKT

ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Mystic Asset Management's IKT Position: Q1 2022 in Review

Mystic Asset Management sold out of Inhibikase Therapeutics (IKT) in Q1 2022, closing a stake of 379 shares — an estimated $3K sold.

Mystic Asset Management first reported a position in IKT in Q4 2021 and held it in 1 quarter. The position peaked at $3K in Q4 2021. 24 funds tracked by Wall St. Rank hold IKT as of Q1 2022.

  • Mystic Asset Management reported no remaining Inhibikase Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Mystic Asset Management sold 379 Inhibikase Therapeutics shares in Q1 2022, an estimated $3K.
  • Mystic Asset Management first reported a position in Inhibikase Therapeutics in Q4 2021 and held it in 1 quarter.
  • Mystic Asset Management's Inhibikase Therapeutics position peaked at $3K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2022.

Based on Mystic Asset Management's 13F filing for Q1 2022, filed 11 May 2022.